Barclays’s Actinium Pharmaceuticals ATNM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-1
| Closed | -$1 | – | 5042 |
|
|
2025
Q4 | $1 | Sell |
1
-3
| -75% | -$4 | ﹤0.01% | 5189 |
|
|
2025
Q3 | $7 | Sell |
4
-2,504
| -100% | -$4.08K | ﹤0.01% | 5408 |
|
|
2025
Q2 | $3.51K | Sell |
2,508
-37,363
| -94% | -$55.9K | ﹤0.01% | 5000 |
|
|
2025
Q1 | $64.2K | Sell |
39,871
-9,989
| -20% | -$12.7K | ﹤0.01% | 4550 |
|
|
2024
Q4 | $62.8K | Buy |
49,860
+6,925
| +16% | +$10.7K | ﹤0.01% | 4708 |
|
|
2024
Q3 | $80.7K | Buy |
42,935
+32,784
| +323% | +$130K | ﹤0.01% | 4624 |
|
|
2024
Q2 | $75.1K | Sell |
10,151
-9,218
| -48% | -$75.9K | ﹤0.01% | 4040 |
|
|
2024
Q1 | $152K | Sell |
19,369
-18,347
| -49% | -$118K | ﹤0.01% | 4250 |
|
|
2023
Q4 | $192K | Buy |
37,716
+33,064
| +711% | +$170K | ﹤0.01% | 4438 |
|
|
2023
Q3 | $27.5K | Sell |
4,652
-533
| -10% | -$3.55K | ﹤0.01% | 4085 |
|
|
2023
Q2 | $38.5K | Sell |
5,185
-50,477
| -91% | -$429K | ﹤0.01% | 3944 |
|
|
2023
Q1 | $526K | Buy |
+55,662
| New | +$588K | ﹤0.01% | 3236 |
|
|
2020
Q3 | – | Sell |
-1,583
| Closed | -$18K | – | 5205 |
|
|
2020
Q2 | $18K | Buy |
1,583
+60
| +4% | +$454 | ﹤0.01% | 5217 |
|
|
2020
Q1 | $9K | Sell |
1,523
-430
| -22% | -$3.05K | ﹤0.01% | 5835 |
|
|
2019
Q4 | $13K | Hold |
1,953
| – | – | ﹤0.01% | 6058 |
|
|
2019
Q3 | $14K | Hold |
1,953
| – | – | ﹤0.01% | 6278 |
|
|
2019
Q2 | $14K | Hold |
1,953
| – | – | ﹤0.01% | 6482 |
|
|
2019
Q1 | $28K | Hold |
1,953
| – | – | ﹤0.01% | 6205 |
|
|
2018
Q4 | $23K | Buy |
1,953
+286
| +17% | +$4.88K | ﹤0.01% | 5832 |
|
|
2018
Q3 | $37K | Hold |
1,667
| – | – | ﹤0.01% | 6227 |
|
|
2018
Q2 | $32K | Buy |
1,667
+667
| +67% | +$8.45K | ﹤0.01% | 5920 |
|
|
2018
Q1 | $11K | Buy |
1,000
+500
| +100% | +$8.5K | ﹤0.01% | 6625 |
|
|
2017
Q4 | $10K | Hold |
500
| – | – | ﹤0.01% | 6507 |
|
|
2017
Q3 | $9K | Hold |
500
| – | – | ﹤0.01% | 6156 |
|
|
2017
Q2 | $18K | Hold |
500
| – | – | ﹤0.01% | 5833 |
|
|
2017
Q1 | $23K | Hold |
500
| – | – | ﹤0.01% | 5735 |
|
|
2016
Q4 | $13K | Buy |
+500
| New | +$15.6K | ﹤0.01% | 5800 |
|
|
2015
Q3 | – | Sell |
-14
| Closed | -$1K | – | 6817 |
|
|
2015
Q2 | $1K | Sell |
14
-9
| -39% | -$768 | ﹤0.01% | 6900 |
|
|
2015
Q1 | $2K | Sell |
23
-17
| -43% | -$2.02K | ﹤0.01% | 6852 |
|
|
2014
Q4 | $6K | Buy |
40
+33
| +471% | +$6.27K | ﹤0.01% | 6918 |
|
|
2014
Q3 | $1K | Sell |
7
-8
| -53% | -$1.59K | ﹤0.01% | 7491 |
|
|
2014
Q2 | $3K | Buy |
+15
| New | +$5K | ﹤0.01% | 7260 |
|
Other funds holding ATNM
VCM
GS
VFT
Barclays's ATNM Position: Q1 2026 in Review
Barclays sold out of Actinium Pharmaceuticals (ATNM) in Q1 2026, closing a stake of 1 share — an estimated $1 sold.
Barclays first reported a position in ATNM in Q2 2014 and held it in 32 quarters. The position peaked at $526K in Q1 2023. 54 funds tracked by Wall St. Rank hold ATNM as of Q1 2026.
- Barclays reported no remaining Actinium Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Barclays sold 1 Actinium Pharmaceuticals share in Q1 2026, an estimated $1.
- Barclays first reported a position in Actinium Pharmaceuticals in Q2 2014 and held it in 32 quarters.
- Barclays's Actinium Pharmaceuticals position peaked at $526K in Q1 2023.
- 54 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.